Fotemustine in the Treatment of Brain Primary Tumors and Metastases

References

• Walker M D, Alexander E, Hunt W E, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1987; 4: 333–343
   Google Scholar
• Kornblith P L, Walker M. Review article. Chemotherapy for malignant gliomas. J Neurol Neurosurg Psychiatry 1988; 68: 1–17
   Google Scholar
• Edwards M S, Levin V A, Wilson C B. Brain tumor chemotherapy: An evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 1980; 12: 1179–1205
   Google Scholar
• Gordon B H, Richards R P, Hiley M P, et al. A new method for the measurement of nitrosoureas in plasma: An H.P.L.C. procedure for measurement of fotemustine kinetics. Xenobiotica 1989; 19: 329–339
   PubMed Web of Science ®Google Scholar
• Meulemans A, Giroux B, Hannoun P, et al. Permeability of two nitrousoureas, carmustine and fotemustine in rat cortex. Chemotherapy 1989; 35: 313–319
   PubMed Web of Science ®Google Scholar
• Meulemans A, Giroux B, Hannoun P, et al. Comparative diffusion study of two nitrosoureas: Carmustine and fotemustine in rat cortex. Chemotherapy 1991; 37: 86–92
   PubMed Web of Science ®Google Scholar
• Rigal-Huguet F, Gaspard M H, Attal M, et al. Pharmacocinétique clinique de la fotémustine à hautes doses avec étude du passage de la barrière hémoméningée. Bull Cancer 1990; 77: 599
   Google Scholar
• Frenay M, Giroux B, Khoury S, et al. Phase II study of a new nitrosourea, fotemustine, in recurrent supratentorial malignant gliomas. Eur J Cancer 1991; 27: 852–856
   PubMed Web of Science ®Google Scholar
• WHO. Handbook for reporting results of cancer treatment. WHO offset publication, Geneva 1979; 45–48
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Khayat D, Lokiec F, Bizzari J P, et al. Phase I clinical study of the new amino acid linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 1987; 47: 6782–6785
   PubMed Web of Science ®Google Scholar
• Hochberg F H, Pruitt A A, Beck D O, et al. The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 1985; 63: 876–880
   PubMed Web of Science ®Google Scholar
• Biron P, Veysseyre M, Chauvin F, et al. Strategy including surgery BCNU high dose followed by ABMT and radiotherapy in supratentorial high grade astrocytoma. Réunion Internationale de la Société Frančaise de Neurologie, Paris June 13–14, 1991; 19, A report of 98 patients
   Google Scholar
• Fauchon F, Davila L, Chatellier G, et al. Treatment of malignant gliomas with surgery, intra-arterial infusions of HeCNU and radiation therapy. A phase II study. Neurosurgery 1990; 27: 231–239
   PubMed Web of Science ®Google Scholar
• Shapiro W R, Green S B. Reevaluating the efficacy of intra-arterial BCNU. Letter to the Editor. J Neurosurg 1987; 66: 313–314
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Zabbe C, Gouva S, et al. Phase II multicentric study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. Eur J Cancer Clin Oncol 1989; 25: 1651–1652
   PubMedGoogle Scholar
• Jacquillat C, Khayat D, Banzet P, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25: 263–266
   PubMed Web of Science ®Google Scholar
• Siegers H P. Chemotherapy for brain metastases: Recent developments and clinical considerations. Cancer Treat Rep 1990; 17: 63–76
   Google Scholar
• Trillet V, Catajar J F, Croisile B, et al. Cerebral metastases as first symptom of bronchogenic carcinoma. A prospective study of 37 cases. Cancer 1991; 67: 2935–2940
   PubMed Web of Science ®Google Scholar
• Frenay M, Bizzari J P, Prady R, Association for Therapeutic Cancer Research (ARTAC). Potential activity of fotemustine in brain metastasis (BM) originated from tumors other than melanoma: Preliminary results of an ARTAC cooperative phase II screening program. Ann Oncol 1990; I(Suppl)122
   Google Scholar
• Gralla R J, Casper E S, Kelsen D P, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414–420
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Riviere A, Benoliel C, et al. Fotemustine-cisplatin combination in advanced non small cell lung carcinoma: Preliminary results of a phase II pilot study. 17th International Congress of Chemotherapy, Berlin, 1991, no. 1948
   Google Scholar
• Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicentric phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873–1878
   PubMed Web of Science ®Google Scholar
• Boote D J, Barnardo P, Sheikh N, et al. Evaluation of fotemustine in metastatic malignant melanoma (MMM): A phase II study. ECCO V Londres 1989
   Google Scholar
• Calabresi F, Aapro M, Becquart D, et al. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol 1991; 2: 377–378
   PubMed Web of Science ®Google Scholar
• Schallreuter K U, Wenzel E, Brassow F W, et al. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991; 29: 85–87
   PubMed Web of Science ®Google Scholar
• Merimsky O, Inbar M, Reider-Grosswasser I, et al. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma. Eur J Cancer 1991; 27: 1066
   PubMed Web of Science ®Google Scholar
• Avril M F, Bonneterre J, Cupissol D, et al. Fotemustine and dacarbazine (DTIC): A combined regimen for malignant melanoma—Final report on 103 evaluable patients. Proc Am Soc Clin Oncol Houston 1991; 1040(10)297
   Google Scholar
• Aamdal S, Lee S M, Radford J A, et al. Sequential administration of dacarbazine (DTIC) and fotemustine (F) in disseminated melanoma. Proc Am Assoc Cancer Res, Houston 1991; 32(1138)191
   Google Scholar
• Kleeberg U R, Engel E, Israels P, et al. Phase II trial of fotemustine (FM) in patients with metastatic melanoma (EORTC-MCG 18881). Onkologie 1991; 14: 81–83
   Google Scholar
• Jones A, Avril M F, O'Brien M, et al. Intermediate results of a phase II trial: Sequential fractionated administration of low dose dacarbazine (DTIC) and fotemustine in disseminated malignant melanoma (DMM). Eur J Cancer 1991, Suppl 2: S 153
   Google Scholar
• Khayat D, Borel C, Karila A, et al. Pilot study of fotemustine (FTMU), dacarbazine (DTIC) and vindesine (VDS) in the treatment of metastatic malignant melanoma (MMM). Proc Am Assoc Cancer Res 1991; 32: 206
   Google Scholar